Menu
← Oncology Approval Tracker
FDA DECISION ·
Brukinsa tablets
zanubrutinib · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A 160 mg tablet formulation for adults with relapsed or refractory marginal zone lymphoma after at least one regimen containing an anti-CD20 therapy.
LAMPGEN ANALYSIS
Why it matters
This formulation action retains accelerated status for the prior anti-CD20-treated marginal zone lymphoma population.
What research teams should watch
Verify exposure to an anti-CD20 agent rather than recording only the overall number of prior lines.
PRIMARY RECORDS